Drug Price Control Revision for Coronary Stents Effective April 2026

The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, has issued a notification revising the ceiling price of Coronary Stents. This update continues a series of price fixation orders issued since 2018 under the Drugs (Prices Control) Order (DPCO), 2013.

The revision is based on the Wholesale Price Index (WPI) increase of 0.64956% for the year 2025 over 2024. Accordingly, the revised ceiling prices (exclusive of GST) will come into effect from 01 April 2026. Manufacturers and importers are permitted to adjust the Maximum Retail Price (MRP) where it is below the ceiling price, strictly in line with Paragraph 16(2) read with Paragraph 13(2) of DPCO, 2013.

Further, GST can only be added if actually paid or payable. Retailers and dealers must display updated price lists prominently as per Para 24(4). Non-compliance with ceiling price norms will attract recovery of overcharged amounts along with interest under DPCO, 2013, and the Essential Commodities Act, 1955.